The Agenda
Agenda – What’s on when
7:00 – 7:55
Registration and Check-in Light Breakfast Served
7:55 – 8:00
Genomic Workshop – Welcome and Learning Objectives
Scientific Program Committee
Maher Albitar, MD – CEO, Genomic Testing Cooperative
Gustavo Rivero, MD, – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute
Anne Renteria MD – Site Director, Transplantation & Cellular Therapy Program, Perlmutter Cancer Center, NYU Langone Health
David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute
8:00 – 9:00
Session Introduction to Myeloid Genomics
Session Chair Introduction
8:00-8:15
8:15-8:30
8:30-9:00
9:00 – 10:00
Session 1: Myeloid Leukemogenesis
This session is eligible for up to 1 ABPath MOC credit.
Session Chair Introduction
Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute
9:00-9:20
Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute
9:20-10:00
Maher Albitar, MD – CEO, Genomic Testing Cooperative
David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute
10:00-10:15
Coffee Break
10:15-11:30
Session 2: Myelodysplastic Syndrome
Session Chair Introduction
David Sallman, MD – Section Head, Leukemia and Myelodysplastic Syndrome, Moffitt Cancer Center
10:15-10:40
David Sallman, MD – Section Head, Leukemia and Myelodysplastic Syndrome, Moffitt Cancer Center
10:40-11:00
Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute
11:00-11:30
David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute
11:30-11:55
Lunch is being combined with the product theater below
13:00 – 14:00
Session 3: Myeloproliferative Neoplasm
Session Chair Introduction
13:00-14:00
14:00-14:10
Coffee Break
14:10-15:10
Session 4: Lymphomas
Session Chair Introduction
14:10-14:40
14:40-15:00
15:00-16:00
Session 5: Multiple Myeloma
Session Chair Introduction
15:00-15:20
15:20-15:40
Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute
15:40-16:00
Saturday – May 17, 2025
7:00-7:55
Registration and Check-in Light Breakfast
7:55-8:00
Hematologic Malignancies Symposium – Welcome and Learning Objectives
Scientific Program Committee
Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute
Anne Renteria, MD – Site Director, Transplantation & Cellular Therapy Program, Perlmutter Cancer Center, NYU Langone Health
David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute
8:00 – 8:30
Featured Lecture
Session Chair Introduction
Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute
8:00-8:30
Tiphaine Martin, MEng, PhD – Assistant Professor – Computational Biologists, Bioinformatics & Biostatistics, Icahn School of Medicine at Mount Sinai
8:30 – 8:45
Breakfast
8:45-9:10
First -Line Treatment Option For Lower-Risk MDS: COMMANDS Trial Overview
Carmelo Alonso, PharmD – Director, US Medical Hematology, Bristol Myers Squibb
9:10-9:55
Session 1: Implementing a Clonal Hematopoiesis Clinic
Session Chair Introduction
Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute
9:15-9:35
9:35-9:55
9:55-10:55
Session 2: Myelodysplastic Syndrome
Session Chair Introduction
9:55-10:15
10:15-10:35
10:35-10:55
David Sallman, MD – Section Head, Leukemia and Myelodysplastic Syndrome, Moffitt Cancer Center
10:55-11:55
Session 3: Racial Disparity and Myeloid Malignancies
Session Chair Introduction
Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute
10:55-11:15
Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute
11:15-11:35
Lacey Williams, MD – Assistant Professor, University of North Carolina
11:35-11:55
11:55-12:15
Lunch
12:15-13:30
Tampa General Hospital Cancer Institute Sponsored Session:
HTLV from Discovery to Genomics
Session Co-Chairs
Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute
12:15-12:40
12:40-13:05
13:05-13:30
13:30-15:15
Session 4: AML Highlights – What Physicians Should Know
Session Chair Introduction
David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute
13:30-13:50
Rory Shallis, MD – Assistant Member, Malignant Hematology Department, Moffitt Cancer Center
13:50-14:10
Manja Meggendorfer, PhD – Head, Molecular Genetics, Munich Leukemia Laboratory
14:10-14:30
David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute
14:30-14:50
Jeffrey Lancet, MD – Senior Member and Chair, Department of Malignant Hematology, Moffitt Cancer Center
14:50-15:15
Sergio Rutella, MD – Director, Nottingham Trent University John van Geest Cancer Research Centre, United Kingdom
15:15-15:30
Coffee Break
15:30-16:50
Session 5: Cellular Therapy
Session Chair Introduction
15:30-15:50
15:50-16:10
16:10-16:30
16:30-16:50
16:50
